Dassault Systèmes and the FondaMental Foundation Launch a Sovereign and Secured Nationwide Health Data Warehouse in France Dedicated to Psychiatry
VELIZY-VILLACOUBLAY, France--(BUSINESS WIRE)-- Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) and the FondaMental Foundation today announced their collaboration to deploy a nationwide Health Data Warehouse (HDW) in France dedicated to psychiatry. This project aligns with France's 2025 public health priorities: strengthening diagnostic and therapeutic research and innovation capabilities by structuring and leveraging complex clinical data within a sovereign and highly secure framework, to improve the understanding, diagnosis and treatment of psychiatric disorders.
Through the deployment of this Health Data Warehouse, Dassault Systèmes—with its OUTSCALE brand—addresses the growing needs for health data security for processing and analysis. It supports the FondaMental Foundation's work on complex conditions such as bipolar disorders, schizophrenia, treatment-resistant depression, and autism spectrum disorders.
The OUTSCALE sovereign cloud, certified for Health Data Hosting and qualified SecNumCloud 3.2 by ANSSI, meets the highest standards for protecting sensitive data, especially health data. It provides a high-performance, sovereign, and scalable cloud environment, combining computing power, trusted infrastructure, and an optimized network to advance scientific understanding of mental health conditions while enabling more precise and personalized care approaches.
Created by France's Ministry of Higher Education and Research, the FondaMental Foundation is a scientific cooperation foundation dedicated to psychiatric research and improving care. It coordinates a network of 54 Expert Centers, each specialized by pathology, where patients are referred by medical professionals to undergo comprehensive assessments (somatic, psychiatric, and neuropsychological). These evaluations enable the development of personalized therapeutic programs. During this process, a large volume of clinical data and biological samples is collected—with patients' consent—then anonymized and compiled into extensive databases and biobanks. More than 20,000 patients are seen in consultation and 6,000 diagnosed. Over 2,000 clinical variables are collected per patient in each Expert Center.
This Health Data Warehouse will enable:
Improved patient monitoring and optimized care pathways, especially through better coordination between psychiatrists, general practitioners and specialists.
Refined diagnoses and the development of new therapeutic strategies.
The integration of artificial intelligence (AI) in mental health, with the capacity to embed machine learning models for advanced analyses, similar to current applications in medical imaging for analyzing X-rays, MRIs, or CT scans with high precision.
'This project equips us with a foundational tool for psychiatric research. By consolidating multimodal data in a secure and sovereign environment, it paves the way for better understanding of psychiatric disorders, more accurate diagnoses, and more suitable treatments. Thanks to this collaboration with Dassault Systèmes, we are reinforcing our commitment to precision psychiatry, serving both patients and healthcare professionals,' said Marion Leboyer, Executive Director of the FondaMental Foundation.
Building on this successful collaboration, Dassault Systèmes aims to expand this approach to other pathologies such as rare diseases, cardiovascular conditions, diabetes, neuroscience, and associated healthcare institutions. This vision stems from a strong conviction: to redefine the medicine of tomorrow through intelligent and secure use of health data.
'By partnering with the FondaMental Foundation, we are putting innovation at the service of mental health research—secure, compliant, and powered by the most advanced technologies. This secure Health Data Warehouse paves the way for a new collective momentum around health data, for the benefit of all. It embodies a bold ambition: to build, together, a more personalized, predictive, and human-centered medicine, driven by AI and the cloud—a true reference model for other institutions looking to engage in this transformation,' said Philippe Miltin, CEO, OUTSCALE, Dassault Systèmes.
This announcement is part of Dassault Systèmes' ongoing work on mental health and psychiatric conditions. True to its vision of digital transformation for healthcare, the company is strengthening its commitment by integrating cutting-edge technologies. Among these innovations are the virtual twin in healthcare—for data modeling, simulation, and data intelligence—and MEDIDATA, for the virtualization of clinical trials. These are central to providing solutions tailored to mental health challenges, and enhancing research and treatment processes.
About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes' 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: www.3ds.com
About FondaMental Foundation: Innovating to Overcome Mental Illness
Created in 2007 at the initiative of the French Ministry of Research and dedicated to scientific collaboration in the field of severe mental illnesses, the FondaMental Foundation has the following missions: to advance cutting-edge research, to innovate in diagnosis and patient monitoring, to train professionals, to inform the public, and to bring together all stakeholders in the field of psychiatry. The Foundation focuses its efforts on schizophrenia, bipolar disorder, treatment-resistant depression, and autism spectrum disorders, in order to provide hope-driven solutions to the scientific and medical community, patients, and their families. Recognized as a public-interest organization, the FondaMental Foundation relies on both public and private funding to promote and share French scientific knowledge internationally, achieve significant results quickly, and ultimately overcome mental illness. Discover our work at: www.fondation-fondamental.org
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
We Need to Talk About Erectile Dysfunction: 38% of Canadian Men Don't Know You Need a Prescription for ED Medication
TORONTO--(BUSINESS WIRE)--For Men's Health Week (June 9 to 15), Phoenix, Canada's leading digital health clinic for men, is raising awareness to break the stigma around erectile dysfunction (ED), a medical condition that affects almost half (49.4%) of Canadian men aged 40 to 88. Thirty-eight per cent of men are unsure or don't think they need a prescription to purchase medication, such as Viagra, for ED. ED is a medical condition that prevents the ability to get and maintain an erection sufficient for sexual intercourse, with a range of potential causes that could each contribute to the condition, including age, medications, injury, and lifestyle. Despite its prevalence, Phoenix's survey of more than 1,500 Canadians found that there is a significant lack of awareness around ED and its treatment, likely contributing to stigma surrounding the condition. CANADIANS UNDERESTIMATE THE REACH OF ED Despite nearly half of Canadian men over 40 being affected, ED's prevalence is underestimated, driving undue stigma. In fact, almost half of Canadians (45%) think that ED affects less than 40 per cent of men 40+. Twenty-seven per cent of Canadians think it affects less than 30 per cent of men 40+. While Canadians underestimate the prevalence of ED in middle-aged and older men, many are also unaware that the condition can also impact younger men. The survey found that 64 per cent of Canadians don't know that men aged 35 and younger can experience ED. That percentage grows as you look at younger men, with 71% of Canadians unaware that men aged 18 to 25 can be affected. This common misconception can contribute to the stigma around experiencing ED as a younger man, making it more difficult for those struggling to seek care. 'ED is a medical condition that men of all ages can experience. There shouldn't be anything awkward about it, but there is. We're trying to change that," says Kevin Bache, co-founder and co-CEO of Phoenix. "While it may feel uncomfortable, men need to understand what the condition entails, and not shy away from being proactive in discussing it with a doctor. The sooner you get started, the better your chances are at finding mental and physical relief." WIDESPREAD MISUNDERSTANDING OF ED MEDICATION Treatment for ED and its underlying cause can vary greatly depending on a patient's prognosis, however, medication is a common and effective treatment. Despite this fact, Phoenix's survey found 18 per cent of men are unsure if ED is treatable with medication, revealing a lack of awareness that may leave many suffering needlessly. The data also highlighted a concerning gap in awareness that ED medication requires a prescription. Thirty-eight per cent of men are unsure or don't think they need a prescription to purchase medication, such as Viagra, for ED. However, the lack of awareness is most significant among younger Canadians. About three in five Gen Z (59%) don't know that you need a prescription for ED medication: 32 per cent are unsure, and 27 per cent don't think you need a prescription at all. It is important that Canadians know that ED medication requires a prescription from a medical professional, as they may otherwise be vulnerable to purchasing unauthorized sexual enhancement products sold over the counter, which Health Canada warns could pose serious health risks. 'It's no surprise that people aren't aware of the prevalence of ED – it just doesn't get talked about enough. But the good news is, there are treatment options, and with more openness and awareness, more people can seek support immediately,' says Gavin Thompson, co-founder and co-CEO of Phoenix. 'We built Phoenix to change that. Our mission is simple: make expert care easy to access – fast, discreet, and doctor-led. We're building a future where men take charge of their health with confidence.' WHAT CANADIANS NEED TO KNOW ABOUT ED ED can affect men at any age, but it becomes more common as you get older. ED is more common than you may think, affecting almost half of Canadian men aged 40 to 88. Many factors can cause ED, including: low levels of testosterone, nervous dysfunction, blood flow complications, medications, medical conditions, lifestyle factors, obesity, diet, drug abuse, smoking, and emotional or psychological complications. ED is highly treatable, but the first step is consulting a medical professional. Treatment for erectile dysfunction and its underlying cause can vary greatly, making it important to consult a medical professional to receive a diagnosis and devise an effective treatment strategy. ED medication requires a prescription from a medical professional. Phoenix is currently available in Ontario, Alberta, British Columbia, Saskatchewan, Manitoba, Nova Scotia, New Brunswick, PEI, and Newfoundland. To learn more about Phoenix's ED support, visit ABOUT PHOENIX Phoenix is Canada's leading digital health clinic for men, specializing in three areas of treatment – erectile dysfunction, weight loss, and hair loss. The telehealth platform facilitates access to licensed Canadian physicians, treatment options, and free, discreet shipping of prescription medication from coast to coast. Visit to learn more. SURVEY METHODOLOGY These findings are from a survey conducted by Phoenix from May 20th to May 22nd, 2025, among a representative sample of 1509 online Canadians who are members of the Angus Reid Forum. The survey was conducted in English and French. For comparison purposes only, a probability sample of this size would carry a margin of error of +/-2.53 percentage points, 19 times out of 20.
Business Wire
6 hours ago
- Business Wire
Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing
LEIDEN, Netherlands--(BUSINESS WIRE)--Azafaros, a clinical-stage biotechnology company developing novel therapies for rare lysosomal storage disorders (LSDs), today announced that it will present at the 2025 BIO International Convention taking place in Boston, USA, from 16-19 June. The company's presentation is scheduled for . Upcoming presentation at BIO 2025 follows successful Series B funding round and encouraging data from ongoing trials The presentation will highlight Azafaros' progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). This announcement follows Azafaros' recently completed and oversubscribed €132 million Series B financing round, which will support advancing nizubaglustat into pivotal clinical development. The company is on track to initiate two Phase 3 trials in GM1/GM2 gangliosidoses and NPC in 2025. Earlier this year, Azafaros reported positive topline results from its ongoing Phase 2 study evaluating nizubaglustat in patients with GM2 gangliosidosis and NPC. The current Ph2 extension study demonstrated a favorable safety profile after more than 12 months of treatment. In addition, preliminary improvements or stabilization in key clinical endpoints were observed in the majority of patients, underscoring promising efficacy trends for nizubaglustat. 'We are excited to share our latest progress at BIO 2025, including the continued clinical development of nizubaglustat which holds strong potential as a meaningful treatment option for patients with devastating neurodegenerative lysosomal disorders,' said Stefano Portolano, CEO at Azafaros. 'With the support of our recent financing round and encouraging data from our ongoing trials, we can continue our rapid momentum to bring this product into pivotal clinical studies as we work to develop a potential new solution for this area where there is a significant unmet need.' About nizubaglustat Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). Nizubaglustat has received Rare Paediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC, Orphan Drug Designations (ODD) for GM1 and GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC, as well as Fast Track Designation and IND clearance for GM1/GM2 gangliosidoses and NPC from the US Food and Drug Administration (FDA). Additionally, nizubaglustat has been awarded Orphan Medicinal Product Designation (OMPD) for the treatment of GM1 and GM2 gangliosidoses by the European Medicines Agency (EMA) and Innovation Passport for the treatment of GM1 and GM2 gangliosidoses from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). About GM1 and GM2 gangliosidoses GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS). This results in progressive and severe neurological impairment and premature death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available. About Niemann-Pick disease Type C (NPC) Niemann-Pick disease Type C is a progressive, life-limiting neurological lysosomal storage disorder caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood. About Azafaros Azafaros is a clinical-stage company founded in 2018 with a deep understanding of rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC and is led by a team of highly experienced industry experts. Azafaros aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. By applying its knowledge, network and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them. Azafaros is supported by leading healthcare investors including Jeito Capital, Forbion Growth, Seroba, Pictet Group and a syndicate of leading Dutch and Swiss existing investors including Forbion Ventures, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.
Yahoo
10 hours ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
